Original Research
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
You Cannot Manage What You Cannot Measure
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
A Teachable Moment in Health Benefits Design
Counting on a Run of Value-Based Benefit Design
Response-Guided Therapy an Appropriate Tool for Evaluating Treatment Protocols and Costs of Drug Therapies
Employers’ Obesity Initiatives in the Workplace: A Wakeup Call for Health Plans
Michael Naslund, MD, MBA, Michael Eaddy, PharmD, PhD, Susan L. Hogue, PharmD, MPH, Eric J. Kruep, PharmD, MS, Manan B. Shah, PharmD, PhD
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?
Andrea Henry, PharmD, MBA, Goldina Ikezuagu Erowele, PharmD, Uche Anadu Ndefo, PharmD, BCPS, Jackie Milton-Brown, PharmD, Enock Anassi, PharmD, MD, Wendy Green, PharmD, MPA, Adriana Alvidrez, PharmD, BCPS, Alphonsus U. Okpara, PharmD
A Collaborative Approach to Drug Selection, Driven by Clinical Outcomes Excellence
When More Is Almost Always Better
Eric Q. Wu, PhD, Paul E. Greenberg, MA, Rym Ben-Hamadi, MSc, Andrew P. Yu, PhD, Elaine H. Yang, PhD, M. Haim Erder, PhD
Efficacy and Cost-Effectiveness: Escitalopram versus Citalopram
Health Plans Must “COPE” with Chronic Diseases
